What Praxis Precision Medicines, Inc. does.

We are a fully integrated, leading central nervous system, or CNS, precision neuroscience biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders. We are applying genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms, using our understanding of shared biological targets and circuits in the brain. Each platform currently has multiple programs, with significant potential for additional program and indication expansion:

• Cerebrum ™, our small molecule platform, utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies

• Solidus ™, our antisense oligonucleotide, or ASO, platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology

Revenue and profit, by fiscal year.

More on PRAX.

• Praxis Precision Medicines, Inc. summary
• Praxis Precision Medicines, Inc. financial statements
• Praxis Precision Medicines, Inc. key metrics
• Praxis Precision Medicines, Inc. health scores and style box
• Praxis Precision Medicines, Inc. earnings
• Praxis Precision Medicines, Inc. dividends
• Praxis Precision Medicines, Inc. valuation
• Praxis Precision Medicines, Inc. ownership and insiders
• Praxis Precision Medicines, Inc. peers

Figures from Praxis Precision Medicines, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.